Figure 3.

(a) Model‐predicted ADC exposure (AUC_0–inf) for patients (n = 314) receiving brentuximab vedotin administered intravenously at 1.8 mg/kg every 3 weeks with the dose capped at 180 mg. The box‐and‐whisker plots indicate minimum and maximum values (lower and upper whiskers), median (heavy band), and first and third quartiles (bottom and top of box). (b) Model‐predicted typical patient ADC concentration–time profiles for male (black line) and female (green line) patients receiving brentuximab vedotin administered intravenously at 1.8 mg/kg every 3 weeks. ADC, antibody‐drug conjugate.